The effect of 17-alpha-hydroxy-19-norprogesterone caproate (SH582) on benign prostatic hypertrophy.
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D002986:Clinical Trials as Topic; D004342:Drug Hypersensitivity; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D010919:Placebos; D011278:Pregnanes / Q000009:adverse effects / Q000627:therapeutic use*; D011372:Progestins / Q000009:adverse effects / Q000627:therapeutic use; D011467:Prostate / Q000000981:diagnostic imaging; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011776:Pyuria / Q000150:complications; D013961:Thyroid Gland / Q000187:drug effects; D014546:Urinary Catheterization; D014567:Urography
D010919:Placebos; D011278:Pregnanes; D011372:Progestins; D000135:Acid Phosphatase